LOG-AFTER software to improve long-term monitoring of childhood cancer survivors
LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) / Etude d'Impact du Logiciel LOG-AFTER Sur le Suivi à Long Terme Des Anciens Patients (LOG-I - LOG-Impact Study)
This project will test whether giving childhood cancer survivors access to the LOG-AFTER app (with optional GP linkage) helps them follow recommended long-term screenings.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 320 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | University Hospital, Angers Government |
| Locations | 1 site (Angers, Maine Et Loire) |
| Trial ID | NCT06939322 on ClinicalTrials.gov |
What this trial studies
This is a randomized interventional comparison where survivors are assigned to follow-up with or without access to the LOG-AFTER software. For participants given access, an account is created within five days of the visit and their personalized after-cancer plan (PPAC) is recorded; all participants complete the PAM-13 patient activation questionnaire. The system collects treatment history, late-effect and psychosocial data, and can notify the patient’s general practitioner when activated. The main aim is to compare how the digital tool affects adherence to recommended survivorship screenings and patient activation over routine follow-up.
Who should consider this trial
Good fit: Ideal candidates are survivors treated for cancer or malignant hematologic disease before age 25 who are disease-free or stable without treatment for at least 5 years, have three or more recommended screenings in their survivorship plan, have internet access on a computer or smartphone/tablet, and can give informed consent.
Not a fit: Patients unlikely to benefit include those with a relapse or second cancer within the past 5 years, people without internet access or health insurance, and those under legal protection or deprived of liberty.
Why it matters
Potential benefit: If successful, LOG-AFTER could increase adherence to recommended screenings, improve patient activation, and help detect late complications earlier.
How similar studies have performed: Previous digital survivorship and e-health programs have shown modest improvements in follow-up adherence and patient activation, while LOG-AFTER’s radiotherapy details and GP linkage represent a relatively novel combination.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Previously treated for cancer or malignant hematological pathology before the age of 25 * Without residual disease or with a stable disease without treatment for 5 years or more * Owning a computer, smartphone or equivalent I-Pad/tablet with internet access * Having signed the consent (or their parents if the patient is a minor, or a third party if necessary) * Having 3 or more recommended screenings in their survivorship care plan * No access created to LOG-AFTER before the study or having never connected after opening their account if opening an account dating back 24 months or more at the time of inclusion Exclusion Criteria: * Patient who has relapsed or developed a second cancer with a post-treatment delay \< 5 years * Patient not covered by a health insurance * Patient subject to a legal protection measure, patient deprived of liberty by judicial or administrative decision, patient subject to psychiatric care under duress
Where this trial is running
Angers, Maine Et Loire
- University Hospital of Angers — Angers, Maine Et Loire, France (Recruiting)
Study contacts
- Principal investigator: Charlotte DEMOOR-GOLDSCHMIDT, Dr — University Hospital of Angers
- Study coordinator: Sandra MERZEAU
- Email: samerzeau@chu-angers.fr
- Phone: (+33)2 41 35 59 70
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.